For the year ending 2025-12-31, FOLD had $600K increase in cash & cash equivalents over the period. $29,849K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -27,110 |
| Amortization of debt discount and deferred financing | 2,570 |
| Depreciation and amortization | 7,460 |
| Stock-based compensation | 87,410 |
| Loss on extinguishment of debt | 0 |
| Non-cash changes in the fair value of contingent consideration payable | 0 |
| Foreign currency remeasurement loss | -3,586 |
| Non-cash deferred taxes | 0 |
| Asset impairment charges and other write-offs | -1,138 |
| Accounts receivable | 5,860 |
| Inventories | 111,483 |
| Prepaid expenses and other current assets | 1,382 |
| Accounts payable, accrued expenses, and other current liabilities | 82,777 |
| Other non-current assets and liabilities | -3,685 |
| Payment of contingent consideration | 0 |
| Net cash provided by (used in) operating activities | 33,145 |
| Sale and redemption of marketable securities | 51,269 |
| Purchases of marketable securities | 94,405 |
| Capital expenditures | 3,296 |
| Net cash (used in) provided by investing activities | -46,432 |
| Proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs | 0 |
| Proceeds from equity financing, net of issuance costs | 0 |
| Withholding taxes paid on vested restricted stock units | 18,323 |
| Proceeds from stock options exercised, net | 19,205 |
| Proceeds from warrants exercised, net | 0 |
| Payment of long-term debt | 0 |
| Proceeds from long-term debt, net of issuance costs | 0 |
| Payment of contingent consideration | 0 |
| Payment of finance leases | 272 |
| Net cash provided by financing activities | 610 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 13,277 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 600 |
| Cash, cash equivalents, and restricted cash at the beginning of the year | 216,716 |
| Cash, cash equivalents, and restricted cash at the end of the year | 217,316 |
AMICUS THERAPEUTICS, INC. (FOLD)
AMICUS THERAPEUTICS, INC. (FOLD)